Global COVID-19 Vaccines Market to Reach $60.7 Billion by 2025

Annual Doses of COVID-19 Vaccines estimated at US$255 Million in the year 2020, is projected to reach US$60.7 Billion by 2025. Value of annual doses in China is forecast to stabilize to US$23 billion by 2025, after peaking at US$73 billion in the year 2021.

New York, July 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global COVID-19 Vaccines Industry" - https://www.reportlinker.com/p06097782/?utm_source=GNW
Global percentage of individuals vaccinated by the year 2025 is expected to taper down to 47% by the year 2025 as compared to the 73% estimated for the year 2022.

Vaccinated population in Africa will reach only 12% by the year 2023, a figure that will dwindle to 4% by 2025. In comparison, the percentage of individuals vaccinated in France is expected to touch 92% by the end of 2022. Number of doses administered worldwide is expected to rise to 4,186 million by 2025.

*Select Competitors (Total 358 Featured)*
- AstraZeneca PLC
- Aurobindo Pharma Ltd.
- Amyris, Inc.
- AnGes, Inc.
- Altimmune, Inc.
- Arcturus Therapeutics, Inc.
- ADImmune Corporation
- AdaptVac
- AJ Vaccines
- Batavia Biosciences BV
- ARTES Biotechnology GmbH
- Baylor College of Medicine
- baseclick GmbH
- Barcelona Supercomputing Center
- Akston Biosciences CorporationRead the full report: https://www.reportlinker.com/p06097782/?utm_source=GNW

C
Read the full report: https://www.reportlinker.com/p06097782/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001